Radiopharm Theranostics Limited (RAD.AX)
AUD 0.02
(-8.7%)
AUD 0.02
(-8.7%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 299.22 Thousand AUD | -99.2% |
| 2023 | 37.28 Million AUD | 77.96% |
| 2022 | 20.95 Million AUD | 4222.55% |
| 2021 | 484.75 Thousand AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 FY | 35.63 Million AUD | -4.42% |
| 2024 Q4 | 18.1 Million AUD | 102.58% |
| 2024 Q2 | 21.56 Million AUD | 215.81% |
| 2024 Q1 | 6.82 Million AUD | -65.08% |
| 2024 Q3 | 6.95 Million AUD | -67.75% |
| 2023 FY | 37.28 Million AUD | 77.96% |
| 2023 Q3 | 7.23 Million AUD | -37.96% |
| 2023 Q1 | 3.9 Million AUD | -61.05% |
| 2023 Q4 | 19.54 Million AUD | 170.16% |
| 2023 Q2 | 11.66 Million AUD | 198.44% |
| 2022 Q4 | 10.03 Million AUD | 170.74% |
| 2022 FY | 20.95 Million AUD | 4222.55% |
| 2022 Q3 | 3.7 Million AUD | -46.35% |
| 2022 Q2 | 6.9 Million AUD | 125.22% |
| 2022 Q1 | 3.06 Million AUD | 0.0% |
| 2021 FY | 484.75 Thousand AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 39.57 Million AUD | 99.244% |
| Anatara Lifesciences Ltd | 710.21 Thousand AUD | 57.868% |
| Zelira Therapeutics Limited | 5.94 Million AUD | 94.97% |
| Biome Australia Limited | 7.91 Million AUD | 96.218% |
| Patrys Limited | 4.93 Million AUD | 93.935% |
| Orthocell Limited | 15.36 Million AUD | 98.053% |
| Imugene Limited | 135.09 Million AUD | 99.778% |
| Noxopharm Limited | 7 Million AUD | 95.725% |
| PYC Therapeutics Limited | 60.91 Million AUD | 99.509% |
| Chimeric Therapeutics Limited | 19.76 Million AUD | 98.486% |
| Prescient Therapeutics Limited | 10.89 Million AUD | 97.254% |
| Proteomics International Laboratories Limited | 892.14 Thousand AUD | 66.46% |
| Cynata Therapeutics Limited | 11.12 Million AUD | 97.31% |
| CSL Limited | 7.56 Billion AUD | 99.996% |
| Arovella Therapeutics Limited | 10.78 Million AUD | 97.226% |
| Bio-Gene Technology Limited | 2.76 Million AUD | 89.162% |
| Clinuvel Pharmaceuticals Limited | 31.29 Million AUD | 99.044% |
| Starpharma Holdings Limited | 22.81 Million AUD | 98.689% |
| Nanollose Limited | 12.5 Thousand AUD | -2293.633% |
| Memphasys Limited | 3.67 Million AUD | 91.865% |
| Invex Therapeutics Ltd | 3.34 Million AUD | 91.057% |
| NeuroScientific Biopharmaceuticals Limited | 1.96 Million AUD | 84.774% |
| Amplia Therapeutics Limited | 8.43 Million AUD | 96.453% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | 50.279% |
| Island Pharmaceuticals Limited | 4.12 Million AUD | 92.747% |
| Race Oncology Limited | 14.77 Million AUD | 97.974% |
| Nyrada Inc. | 4.55 Million AUD | 93.431% |
| Telix Pharmaceuticals Limited | 269.26 Million AUD | 99.889% |
| Dimerix Limited | 25.64 Million AUD | 98.833% |
| PharmAust Limited | 6.65 Million AUD | 95.505% |
| Immutep Limited | 42.87 Million AUD | 99.302% |
| Clarity Pharmaceuticals Ltd | 56.3 Million AUD | 99.469% |
| Alterity Therapeutics Limited | 23.4 Million AUD | 98.722% |
| BTC Health Limited | -1.03 Million AUD | 128.802% |
| Acrux Limited | 8.55 Million AUD | 96.5% |
| Neuren Pharmaceuticals Limited | 32.69 Million AUD | 99.085% |
| Biotron Limited | 5.11 Million AUD | 94.145% |
| Tissue Repair Ltd | 6.66 Million AUD | 95.512% |
| AdAlta Limited | 6.76 Million AUD | 95.58% |
| Hexima Limited | 1 Million AUD | 70.337% |
| AnteoTech Limited | 12.18 Million AUD | 97.545% |
| Paradigm Biopharmaceuticals Limited | 65.1 Million AUD | 99.54% |
| Recce Pharmaceuticals Ltd | 21.68 Million AUD | 98.62% |
| Avecho Biotechnology Limited | 4.54 Million AUD | 93.417% |
| Actinogen Medical Limited | 22.77 Million AUD | 98.686% |
| Immuron Limited | 9.13 Million AUD | 96.725% |
| Argenica Therapeutics Limited | 8.26 Million AUD | 96.381% |